Beruflich Dokumente
Kultur Dokumente
doi:10.1093/jac/dki477
Advance Access publication 23 January 2006
Objectives: This study was undertaken to determine the interaction of tigecycline with 13 select
antimicrobial agents against a wide variety of Gram-negative and Gram-positive bacterial isolates.
Methods: Antibiotic interactions were assayed using the chequerboard MIC format and selected synergistic combinations were confirmed using time-kill kinetic analysis.
Results: Microdilution chequerboard analysis of tigecycline in combination with amikacin, ampicillin/
sulbactam, azithromycin, ciprofloxacin, colistin, imipenem, levofloxacin, piperacillin, piperacillin/
tazobactam, polymyxin B, rifampicin, minocycline and vancomycin resulted in an interpretation of either
no interaction or synergy. Time-kill kinetic analysis resulted in an interpretation of no interaction for all but
one of the drug combinations that resulted in an interpretation of synergy by the chequerboard analysis.
Antagonism was not observed for any combination when assayed by either method.
Conclusions: The lack of antagonism seen with tigecycline combinations in both chequerboard and timekill kinetic studies is an encouraging outcome, suggesting that tigecycline may prove to be effective in
combination therapy as well as in monotherapy.
Keywords: antibiotics, synergy, antagonism, susceptibility
Introduction
Tigecycline, the 9-glycylamido derivative of minocycline, is the
first member of the glycylcycline class of antibiotics to enter
the clinic. Tigecycline acts by preventing translation through a
reversible binding interaction that blocks the association of
charged tRNA with the ribosome. Tigecycline has a distinct
advantage over tetracycline and minocycline in that it is not subject
to either the efflux or ribosomal protection mechanisms of
tetracycline resistance.1,2 Preclinical studies have demonstrated
the potent in vitro activity of tigecycline against a broad spectrum
of Gram-positive, Gram-negative, anaerobic and atypical pathogens, including those organisms expressing tetracycline resistance
determinants.1,2 Moreover, tigecycline is active against methicillinresistant Staphylococcus aureus (MRSA), vancomycin-resistant
Enterococcus spp. (VRE), penicillin-resistant Streptococcus
pneumoniae (PRSP) and extended spectrum b-lactamase (ESBL)
producing Klebsiella pneumoniae and Escherichia coli.1 Despite
the potent broad spectrum of activity of tigecycline, supported
.............................................................................................................................................................................................................................................................................................................................................................................................................................
573
The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Downloaded from http://jac.oxfordjournals.org/ at Indian Vetinary Research Institute on December 12, 2012
Received 7 October 2005; returned 16 November 2005; revised 30 November 2005; accepted 12 December 2005
Petersen et al.
Antimicrobial agents
Chequerboard MIC
Antibiotic interactions were determined using the chequerboard MIC
assay as previously described.5 MuellerHinton II broth (MHB) was
used for the Enterobacteriaceae, staphylococci and enterococci and
was supplemented with 5% lysed horse blood for streptococci.
Seven doubling dilutions of tigecycline and 11 doubling dilutions
of the test antimicrobial agent were tested. After drug dilution, microbroth dilution plates were inoculated with each organism to yield
the appropriate density (105 cfu/mL) in a 100 mL final volume and
incubated for 1822 h at 35 C in ambient air.
The FICI was calculated for each combination using the following
formula: FICA + FICB = FICI, where FICA = MIC of drug A in
combination/MIC of drug A alone, and FICB = MIC of drug B in
combination/MIC of drug B alone. The FICI was interpreted as
follows: synergy = FICI 0.5; no interaction = FICI >0.54;
antagonism = FICI > 4.
Time-kill assays
Flasks containing MHB and drug were inoculated with test organism
to a density of 106 cfu/mL in a final volume of 100 mL and incubated in a shaking water bath at 35 C in ambient air. Aliquots were
removed at time 0 and 3, 6 and 24 h post-inoculation and serially
diluted in 0.85% sodium chloride solution for determination of
viable counts. Diluted samples, 0.05 mL, were plated in duplicate
on trypticase soy agar plates using a spiral plater (Don Whitley
Scientific Ltd). Total bacterial cfu/mL (log10cfu/mL) were determined
after 18 h of incubation at 35 C.
574
Downloaded from http://jac.oxfordjournals.org/ at Indian Vetinary Research Institute on December 12, 2012
Tigecycline synergy
Table 1. Results of chequerboard testing of tigecycline and a second
antibacterial agent against Gram-negative bacteria
Organism
Acinetobacter
baumannii
Second agent
No. of strains
showing synergy/total
no. of strainsa
amikacin
ampicillin/sulbactam
azithromycin
ciprofloxacin
colistin
piperacillin/tazobactam
polymyxin B
rifampicin
4/9
1/9
0/9
0/9
1/9
2/9
2/9
1/9
3/11
0/11
3/11
Enterobacter
aerogenes
amikacin
ampicillin/sulbactam
azithromycin
ciprofloxacin
colistin
imipenem
levofloxacin
piperacillin
piperacillin/tazobactam
polymyxin B
rifampicin
1/1
0/1
0/1
0/1
1/1
1/5
4/5
3/5
1/1
0/1
1/1
amikacin
ampicillin/sulbactam
azithromycin
ciprofloxacin
colistin
imipenem
levofloxacin
piperacillin
piperacillin/tazobactam
polymyxin B
rifampicin
2/2
2/2
1/2
0/2
0/2
1/5
1/5
3/5
1/2
0/2
2/2
imipenem
levofloxacin
piperacillin
1/11
0/11
2/11
amikacin
ampicillin/sulbactam
azithromycin
ciprofloxacin
colistin
imipenem
levofloxacin
piperacillin
piperacillin/tazobactam
polymyxin B
rifampicin
3/3
2/3
0/3
0/3
0/3
3/10
3/10
1/10
3/3
0/3
2/3
imipenem
levofloxacin
minocycline
piperacillin
2/4
0/4
3/4
2/4
Enterobacter
cloacae
Escherichia coli
Klebsiella
pneumoniae
Proteus mirabilis
Organism
Second agent
No. of strains
showing synergy/total
no. of strainsa
Proteus vulgaris
imipenem
levofloxacin
minocycline
piperacillin
0/4
1/4
3/4
3/4
Providencia
rettgeri
imipenem
levofloxacin
minocycline
piperacillin
1/3
0/3
2/3
1/3
Pseudomonas
aeruginosa
amikacin
ampicillin/sulbactam
azithromycin
ciprofloxacin
colistin
imipenem
levofloxacin
piperacillin
piperacillin/tazobactam
polymyxin B
rifampicin
0/3
2/3
0/3
0/3
0/3
1/11
0/11
3/11
2/3
0/3
0/3
Stenotrophomonas
maltophilia
imipenem
levofloxacin
piperacillin
0/10
0/10
0/10
Organism
Second agent
No. of strains
showing
synergy/total
no. of strainsa
Staphylococcus
aureus (MRSA)
vancomycin
rifampicin
1/10
2/10
Enterococcus
faecium (VRE)
vancomycin
rifampicin
3/5
4/5
Enterococcus
faecium
vancomycin
rifampicin
1/5
4/5
Enterococcus
faecalis (VRE)
vancomycin
0/3
rifampicin
vancomycin
2/3
0/8
rifampicin
vancomycin
rifampicin
5/8
7/10
10/10
Enterococcus
faecalis
Streptococcus
pneumoniae (PRSP)
a
575
Downloaded from http://jac.oxfordjournals.org/ at Indian Vetinary Research Institute on December 12, 2012
Table 1. (continued)
Petersen et al.
2. Petersen PJ, Bradford PA, Weiss WJ et al. In vitro and in vivo
activities of tigecycline (GAR-936), daptomycin, and comparative
antimicrobial agents against glycopeptide-intermediate Staphylococcus
aureus and other resistant Gram-positive pathogens. Antimicrob Agents
Chemother 2002; 46: 2595601.
3. Rybak MJ McGrath BJ. Combination antimicrobial therapy
for bacterial infections. Guidelines for the clinician. Drugs 1996; 52:
390405.
4. White R, Burgess D, Manduru M et al. Comparison of three different
in vitro methods of detecting synergy: time-kill, checkerboard, and E test.
Antimicrob Agents Chemother 1996; 40: 191418.
5. Rand KH, Houck HJ, Brown P et al. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents
Chemother 1993; 37: 613615.
6. Alou L, Cafini F, Sevillano D et al. In vitro activity of mupirocin and
amoxicillin-clavulanate alone and in combination against staphylococci
including those resistant to methicillin. Int J Antimicrob Agents 2004;
23: 5136.
7. Jacqueline C, Navas D, Batard E et al. In vitro and in vivo
synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother 2005; 49: 4551.
8. Cappelletty DM Rybak MJ. Comparison of methodologies for
synergism testing of drug combinations against resistant strains of
Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40:
67783.
Transparency declarations
None to declare.
References
1. Bradford PA, Weaver-Sands DT Petersen PJ. In vitro activity of
tigecycline against isolates from patients enrolled in phase 3 clinical trials
for complicated skin and skin structure infections and complicated
intra-abdominal infections. Clin Infect Dis 2005; 41 Suppl 5: S31532.
576
Downloaded from http://jac.oxfordjournals.org/ at Indian Vetinary Research Institute on December 12, 2012